How much echo left ventricular hypertrophy would be missed in diabetics by applying the Losartan Intervention For Endpoint Reduction electrocardiogram criteria to select patients for angiotensin receptor blockade?

Adelle Dawson, Bushra S Rana, Stuart D Pringle, Louise A Donnelly, Andrew D Morris, Allan D Struthers

    Research output: Contribution to journalArticle

    7 Citations (Scopus)

    Abstract

    The Losartan Intervention For Endpoint Reduction (LIFE) study demonstrated a clear mortality benefit in treating hypertensive patients with electrocardiogram (ECG) evidence of left ventricular hypertrophy (LVH) with losartan rather than atenolol. Previous studies have also shown that identifying and treating echo LVH is associated with prognostic benefits in hypertensive subjects, and is independent of the presence of ECG LVH. We sought to determine how many cases of echo LVH would be missed by applying the ECG criteria for LVH used in the LIFE study.
    Original languageEnglish
    Pages (from-to)1403-8
    Number of pages6
    JournalJournal of Hypertension
    Volume22
    Issue number7
    DOIs
    Publication statusPublished - 2004

    Fingerprint

    Angiotensin Receptors
    Losartan
    Left Ventricular Hypertrophy
    Electrocardiography
    Atenolol
    Mortality

    Cite this

    @article{73cbaa52e2524cafbd7a43b5e5c8b2b0,
    title = "How much echo left ventricular hypertrophy would be missed in diabetics by applying the Losartan Intervention For Endpoint Reduction electrocardiogram criteria to select patients for angiotensin receptor blockade?",
    abstract = "The Losartan Intervention For Endpoint Reduction (LIFE) study demonstrated a clear mortality benefit in treating hypertensive patients with electrocardiogram (ECG) evidence of left ventricular hypertrophy (LVH) with losartan rather than atenolol. Previous studies have also shown that identifying and treating echo LVH is associated with prognostic benefits in hypertensive subjects, and is independent of the presence of ECG LVH. We sought to determine how many cases of echo LVH would be missed by applying the ECG criteria for LVH used in the LIFE study.",
    author = "Adelle Dawson and Rana, {Bushra S} and Pringle, {Stuart D} and Donnelly, {Louise A} and Morris, {Andrew D} and Struthers, {Allan D}",
    year = "2004",
    doi = "10.1097/01.hjh.0000125408.50839.b8",
    language = "English",
    volume = "22",
    pages = "1403--8",
    journal = "Journal of Hypertension",
    issn = "0263-6352",
    publisher = "Lippincott Williams and Wilkins",
    number = "7",

    }

    How much echo left ventricular hypertrophy would be missed in diabetics by applying the Losartan Intervention For Endpoint Reduction electrocardiogram criteria to select patients for angiotensin receptor blockade? / Dawson, Adelle; Rana, Bushra S; Pringle, Stuart D; Donnelly, Louise A; Morris, Andrew D; Struthers, Allan D.

    In: Journal of Hypertension, Vol. 22, No. 7, 2004, p. 1403-8.

    Research output: Contribution to journalArticle

    TY - JOUR

    T1 - How much echo left ventricular hypertrophy would be missed in diabetics by applying the Losartan Intervention For Endpoint Reduction electrocardiogram criteria to select patients for angiotensin receptor blockade?

    AU - Dawson, Adelle

    AU - Rana, Bushra S

    AU - Pringle, Stuart D

    AU - Donnelly, Louise A

    AU - Morris, Andrew D

    AU - Struthers, Allan D

    PY - 2004

    Y1 - 2004

    N2 - The Losartan Intervention For Endpoint Reduction (LIFE) study demonstrated a clear mortality benefit in treating hypertensive patients with electrocardiogram (ECG) evidence of left ventricular hypertrophy (LVH) with losartan rather than atenolol. Previous studies have also shown that identifying and treating echo LVH is associated with prognostic benefits in hypertensive subjects, and is independent of the presence of ECG LVH. We sought to determine how many cases of echo LVH would be missed by applying the ECG criteria for LVH used in the LIFE study.

    AB - The Losartan Intervention For Endpoint Reduction (LIFE) study demonstrated a clear mortality benefit in treating hypertensive patients with electrocardiogram (ECG) evidence of left ventricular hypertrophy (LVH) with losartan rather than atenolol. Previous studies have also shown that identifying and treating echo LVH is associated with prognostic benefits in hypertensive subjects, and is independent of the presence of ECG LVH. We sought to determine how many cases of echo LVH would be missed by applying the ECG criteria for LVH used in the LIFE study.

    U2 - 10.1097/01.hjh.0000125408.50839.b8

    DO - 10.1097/01.hjh.0000125408.50839.b8

    M3 - Article

    VL - 22

    SP - 1403

    EP - 1408

    JO - Journal of Hypertension

    JF - Journal of Hypertension

    SN - 0263-6352

    IS - 7

    ER -